Keyword: Johnson & Johnson
With resolutions on the ballot at six top U.S. drugmakers, investors aim to learn how drug pricing affects executive pay.
More signs of trouble for Bayer and J&J's Xarelto? As prescriptions flag, the drugmakers blame stepped-up discounts for its U.S. sales woes.
What does it take to run one of pharma’s biggest whales? As J&J CEO Alex Gorsky told Fortune, six years in the U.S. Army made all the difference.
Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.
As sales of blockbuster lung drug Spiriva flagged in 2018, Boehringer Ingelheim needed a boost from other divisions. Turns out diabetes was the key.
Johnson & Johnson faces a serious battle against generics and biosimilars, and that's going to take a bite out of its pharma business this year.
Chinese CDMO GenScript Biotech has started construction on a production facility to specialize in plasmids and viruses manufacturing.
Balversa has become the first FGFR inhibitor approved by the FDA, and it carries Johnson & Johnson's blockbuster hope.
Johnson & Johnson unveiled new data showing how its Invokana can benefit patients with Type 2 diabetes and chronic kidney disease.
J&J, Merck, Pfizer and Abbott reaped a combined $7 billion in savings from two tax reform provisions, and they spent most of it on investor payouts.